Clinical trial
Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip
NCT03949673 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 8, 2019
- Completion date
- August 25, 2020
- Enrollment
- 23 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.